🔬 Pharmidex at "From Innovation to Adoption in Gene Therapies"! 🚀

February 27, 2025

We’re excited to announce that Radhakrishnan Venkatasamy, our Principal Research Scientist specializing in autoimmune diseases, will be attending From Innovation to Adoption in Gene Therapies, hosted by One Nucleus on Thursday, 27 February 2025 at Level 39, Canary Wharf, London.

This event brings together experts to explore the latest advancements in gene therapies, and Radhakrishnan is eager to connect with fellow innovators to discuss new opportunities for collaboration.

Let’s work together to accelerate drug discovery and development!

📍 Event details:

📅 Date: Thursday, 27 February 2025

⏰ Time: 15:00 – 19:30

📍 Location: Level 39, One Canada Square, Canary Wharf, London E14 5AB

🔗 More info: (https://lnkd.in/efEUWfCJ)

💬 Interested in partnering with Pharmidex? Connect with Radhakrishnan at the event or reach out to us!

#GeneTherapy #Pharmidex #DrugDiscovery #BiotechInnovation #Collaboration

< Older Post

Newer Post >

We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist

July 30, 2025

We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist

🎓 Welcoming Future Scientists to Pharmidex! 🎓

July 28, 2025

We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. 👩‍🔬 👨‍🔬 Welcome to the team, Gabrielle and Mohammed!

Does your compound taste good enough for the clinic?

July 24, 2025

At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: ✅ Bitter-tasting APIs ✅ Unpalatable excipients ✅ The success of taste-masking strategies ✅ Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.